Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Pelican Therapeutics
  • Technology
    • gp96 Platform
    • Pelican’s PTX-35 Co-stimulatory Antibody
  • Product Pipeline
    • Overview
    • HS-110
    • HS-130
    • COVID-19 Vaccine
    • PTX-35
    • Expanded Access
    • Scientific Publications
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Corporate Presentation
  • News & Media
    • News Releases
    • Events
  • Careers
  • Contact

News Releases

News & Media

News & Media

  • News Releases
  • Events

Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Feb 28, 2018

UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study

Feb 26, 2018

Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung Cancer

Feb 20, 2018

Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond

Feb 14, 2018

Heat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New York

Feb 7, 2018

Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study

Jan 30, 2018

Heat Biologics Announces Reverse Stock Split

Jan 19, 2018

Heat Biologics Receives FDA Guidance at Type C Meeting for HS-110 Clinical Trial in the Treatment of Non-small Cell Lung Cancer

Dec 7, 2017

Heat Biologics Prices 5,813,950 Shares for Common Stock Offering

Nov 17, 2017

Heat Biologics Announces Proposed Public Offering of Common Stock

Nov 16, 2017
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...25
    © 2021 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn